Four offers and a call from Bourla: How Pfizer narrowly beat out rival bidder to swallow GBT and its sickle cell drugs for $5.4B - Endpoints News

Pfizer wasn’t the first — or only — company that wanted to buy Global Blood Therapeutics. In fact, Pfizer elbowed a rival bidder throughout two months of intense negotiations almost right down to the last minute, according to details revealed in a new SEC fil…

In drug development, the running joke is that you can conduct well-controlled experiments, with a placebo arm and a study drug cohort. “You can’t do that in finance,” as Karuna Therapeutics CFO Troy… [+721 chars]

full article...